Company
L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Inflection Biosciences pipeline includes first-in-class IBL-202, a dual PIM and PI3K inhibitor in development for B-cell malignancies, the IBL-100s (PIM kinase inhibitors) and AUM302, partnered with AUM Biosciences.
Dublin, Dublin, Ireland
Send a message
Anglais
Anglais
Inflection Biosciences Ltd, an award winning biotech ased in Dublin and Boston, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-202 is a first-in-class PIM/PI3K inhibitor with pre-clincial data supporting its potential in B-cell malignancies, T-cell lymphoma and leukemia. The IBL-100 series comprises selective pan-PIM kinase...
Inflection Biosciences Ltd, an award winning biotech ased in Dublin and Boston, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-202 is a first-in-class PIM/PI3K inhibitor with pre-clincial data supporting its potential in B-cell malignancies, T-cell lymphoma and leukemia. The IBL-100 series comprises selective pan-PIM kinase inhibitors with pre-clinical proof of concept in AML and lung cancer. The copmany's partnered pipeline comprises AUM302 is a first-in-class, orally available PIM/PI3K/mTOR inhibitor, partnered with AUM Biosciences, fro which the company wil earn contigent revenue streams. Pre-clincal proof of conept in B-cell malignancies, breast cancer, lung cancer, AML and neuroblastoma has been generated, with results published in peer review journals. The quality of company's research has been recognised in its receipt of funding from the European Union's Horizon 2020 in 2019. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com
1
Followers
1
Like
Start in 31/12/2012
31/12/2012
Inflection Biosciences Ltd incorporated in Dublin, Ireland
28/05/2013
Cancer pipeline secure via licensing agreement with Spanish National Cancer Research Centre (CNIO)
1/10/2014
Awarded Start Up of the year at Pharma Awards
28/5/2018
IBL-202 peer review publication in British Journal of Hematology
1/7/2019
AUM302 out-licensing to AUM Biosciences, Singapore
to be continued ...